Explore Annogen’s News
VectorY and Annogen Announce Research Collaboration for the Development of CNS-cell Specific Promoters
PRESS RELEASE Amsterdam, The Netherlands, 19 January 2023 Annogen to develop multiple CNS-cell specific promoters for VectorY programs VectorY Therapeutics, a biotech company developing innovative vectorized antibody approaches for the treatment of neurodegenerative...
Annogen Announces Research Project with Pfizer to TestNon-coding Genetic Sequences
PRESS RELEASE Amsterdam, 13 December 2022 Annogen will functionally annotate tens of thousands of disease-related non-coding sequence variants with the goal of aiding drug discovery Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the...
Annogen introduces AIM™ service
Identify favorable gene insertions and their expression levels (> 100,000 integrations in parallel) Annogen introduces a new service to identify gene insertions and asses their expression levels for >100,000 integrations in parallel. Using an adaptation of its...
Novel approach could aid selective breeding in cattle
Researchers aim to pinpoint non-gene components in DNA linked to production and welfare traits in cattle, gaining insights across species. Researchers are developing a method of identifying specific letters in the DNA code that govern the development of key physical...
SuRE technology finds hidden gene regulation
Many diseases are determined by differences in yet undiscovered gene regulation. Thanks to plasmids and 'barcodes', the SuRE assay can map this relatively easily and extensively for the entire human genome. 'The breakthrough came from the idea of using barcodes,' says...
Annogen BV, a precision medicine company for the non-coding genome, signs research agreement with top tier pharma company.
PRESS RELEASE Amsterdam, 30 November 2021 Under the agreement Annogen will use its proprietary SuRE™ technology to generate genome-wide regulatory profiles to identify disease-relevant regulatory activity and disease-relevant non-coding sequence variants. Annogen...
Annogen signs collaboration agreement with Tier 1 agricultural firm to research non-coding DNA influencing gene expression using SuRE™ screening technology
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agricultural firm to identify non-coding DNA fragments in plants’ genomes that influence...
Collaboration agreement with a Tier 1 agricultural firm to research non-coding regulatory DNA.
PRESS RELEASE Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, started a collaboration with a Tier 1 agri firm to test non-coding DNA fragments that are predicted to influence...
Annogen and KeyGene to collaborate in research on non-coding DNA influencing gene expression
Annogen, the Amsterdam based biotech company behind the SuRE™ technology for the functional annotation of the non-coding part of the genome, and KeyGene, the Wageningen based research company developing innovative technologies for crop improvement, are to collaborate...
